Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
MannKind Corporation to Present at Upcoming Conferences
-
Longevity Acquisition Corp. (CORP) Prices 4M Unit IPO at $10/Unit
-
Longevity Acquisition Corporation Announces Pricing of $40,000,000 Initial Public Offering
-
Longevity Acquisition Corporation Announces Pricing of $40,000,000 Initial Public Offering
-
Cantor Fitzgerald Starts AnaptysBio (ANAB) at Overweight
-
Athena Blockchain Signs Joint Venture Agreement with Broker-Dealer 303 Alternatives LLC To Bring Compliant Investment Banking Services To The Crypto World
-
Globant S.A. (GLOB) PT Raised to $57 at Cantor Fitzgerald
-
Stifel Hires Adam Vengrow as Head of Credit
-
Cantor Fitzgerald Starts Reata Pharmaceuticals (RETA) at Overweight
-
Cantor Fitzgerald Downgrades Aetna (AET) to Neutral on Limited Upside
-
Cantor Fitzgerald Starts Neurocrine Bio. (NBIX) at Overweight
-
Cantor Fitzgerald Starts Halozyme Therapeutics (HALO) at Overweight
-
Cantor Fitzgerald Starts Vanda Pharmaceuticals (VNDA) at Neutral
-
Cantor Fitzgerald Starts Deciphera (DCPH) at Overweight
-
Cantor Fitzgerald Starts Alder Biopharm (ALDR) at Neutral
-
Cantor Fitzgerald Starts Acadia Pharmaceuticals (ACAD) at Overweight
-
Avino Announces Filing of Form F-3 Shelf Registration Statement
-
Pre-Open Movers 08/21: (TOL) (FN) (TLRY) Higher; (SEAC) (JILL) (AMTD) Lower (more...)
-
Ekso Bionics (EKSO) Enters $25M ATM Offering with Cantor Fitzgerald
-
Inovio Pharmaceuticals to Participate in Upcoming Investment Conferences
-
UPDATE: Cantor Fitzgerald Starts Vital Therapies (VTL) at Overweight
-
After-Hours Stock Movers 08/20: (FN) (VTL) Higher; (NDSN) (APPN) (HTZ) Lower (more...)
-
ViewRay Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
-
Castlight Health Inc. (CSLT) Weakness 'Overdone' - Cantor Fitzgerald
-
Chinese internet stock sell-off may shake faith in FANGs
-
Emergent BioSolutions to Participate in Series of Near-Term Investor Conferences
-
Emergent BioSolutions to Participate in Series of Near-Term Investor Conferences
-
Orchid Island Capital Announces August 2018 Monthly Dividend and July 31, 2018 RMBS Portfolio Characteristics
-
Evolus, Inc. Announces Full Exercise and Closing of Underwriters’ Overallotment Option
-
Max Sound Corporation Midyear Shareholder Update
-
CohBar Announces Second Quarter 2018 Financial Results
-
CohBar Announces Second Quarter 2018 Financial Results
-
Aridis Pharmaceuticals Inc. (ARDS) Prices 2M Share IPO at $13/Sh
-
Aridis Pharmaceuticals Announces Pricing of Initial Public Offering
-
Cantor Raises Envision Healthcare (EVHC) PT To Reflect KKR Deal
-
Cantor Fitzgerald Remains Bullish on Perrigo (PRGO) Despite Guidance Cut
-
Westwater Resources Reports Second Quarter 2018 Operating Results
-
Westwater Resources Reports Second Quarter 2018 Operating Results
-
Collegium Pharmaceutical (COLL) PT Lowered to $35 at Cantor Fitzgerald
-
Cantor Fitzgerald Starts Pacific Biosciences of California (PACB) at Overweight
-
Adverum Biotechnologies Reports Second Quarter 2018 Financial Results and Provides Corporate Update
-
Strongbridge Biopharma (SBBP) PT Raised to $17 at Cantor Fitzgerald
-
AcelRx Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
-
UPDATE: Cantor Fitzgerald Maintains GW Pharma (GWPH) at Overweight, Lowers PT to $211
-
Arrowhead Research (ARWR) PT Raised to $18 at Cantor Fitzgerald
-
Cantor Fitzgerald Maintains Bullish View on Opko Health (OPK) Following Beat
-
Progenics Pharma (PGNX) Prices 9.09M Share Common Offering at $8.25/Sh
-
Progenics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Progenics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Aptose Reports Results for the Second Quarter Ended June 30, 2018


